Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

BACKGROUND/AIM: We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. MATERIALS/METHODS: One hundred fifty two u‐HCC patients, who receive LEN treatment from Marc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiraoka, Atsushi, Kumada, Takashi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639201/
https://www.ncbi.nlm.nih.gov/pubmed/31127698
http://dx.doi.org/10.1002/cam4.2241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639201/
https://www.ncbi.nlm.nih.gov/pubmed/31127698
http://dx.doi.org/10.1002/cam4.2241

Ejemplares similares